Galmed Pharmaceuticals Ltd. (GLMD)

Market Cap	4.46M
Revenue (ttm)	n/a
Net Income (ttm)	-6.32M
Shares Out	1.51M
EPS (ttm)	-13.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,468
Open	3.050
Previous Close	3.000
Day's Range	2.850 - 3.050
52-Week Range	2.730 - 23.800
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 13, 2014
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: GLMD
• Website: https://www.galmedpharma.com